Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: J Occup Environ Med. 2020 Apr;62(4):307–316. doi: 10.1097/JOM.0000000000001828

Table 3.

Findings from the Norfolk Quality of Life – Diabetic Neuropathy (QOL-DN) instrument, the Utah Early Neuropathy Scale, and the Michigan Neuropathy Screening Instrument among paresthesia cases, clinic controls and community controls (higher scores indicate greater neuropathic impairment).

Scale: Cases
[median,
IQR]
(n=41)
Clinic
Controls
[median,
IQR]
(n=38)
Community
Controls
[median,
IQR]
(n=20)
p-
value*
Norfolk Physical Functioning/Large Fiber Score 31 (16,41) 0 (−1,9) 0 (−1,9) < 0.0001
Norfolk Small Fiber Score 2 (1,4) 0 (0,0) 0 (0,0) < 0.0001
Norfolk Total Score 53 (32,70) 2 (−1,9) 0 (−1.5,3.5) < 0.0001
Utah Early Neuropathy Scale 6 (4,10) 0 (0,2) 0 (0,2) < 0.0001
Michigan Neuropathy Screening Instrument 5 (4,7) 1 (0,2) 0 (0,1) < 0.0001
*

p from the Kruskall-Wallis test